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Background: Autism and the fragile X syndrome (FXS) are related to each other genetically and symptomatically. A
cardinal biological feature of both disorders is abnormalities of cerebral cortical brain volumes. We have previously
shown that the monoamine oxidase A (MAOA) promoter polymorphism is associated with cerebral cortical volumes
in children with autism, and we now sought to determine whether the association was also present in children
with FXS.
Methods: Participants included 47 2-year-old Caucasian boys with FXS, some of whom also had autism, as well as
34 2-year-old boys with idiopathic autism analyzed in a previous study. The MAOA promoter polymorphism was
genotyped and tested for relationships with gray and white matter volumes of the cerebral cortical lobes and
cerebro-spinal fluid volume of the lateral ventricles.
Results: MAOA genotype effects in FXS children were the same as those previously observed in idiopathic autism:
the low activity MAOA promoter polymorphism allele was associated with increased gray and white matter
volumes in all cerebral lobes. The effect was most pronounced in frontal lobe gray matter and all three white
matter regions: frontal gray, F = 4.39, P = 0.04; frontal white, F = 5.71, P = 0.02; temporal white, F = 4.73, P = 0.04;
parieto-occipital white, F = 5.00, P = 0.03. Analysis of combined FXS and idiopathic autism samples produced
P values for these regions <0.01 and effect sizes of approximately 0.10.
Conclusions: The MAOA promoter polymorphism is similarly associated with brain structure volumes in both
idiopathic autism and FXS. These data illuminate a number of important aspects of autism and FXS heritability: a
genetic effect on a core biological trait of illness, the specificity/generalizability of the genetic effect, and the utility
of examining individual genetic effects on the background of a single gene disorder such as FXS.
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Autism is a behaviorally defined syndrome characterized
by extensive phenotypic variation and etiological hetero-
geneity. Symptom constellations, disease severity, and as-
sociated biological traits can differ markedly from one
affected individual to another. This is true even in cases
attributable to single genetic defects such as chromosome* Correspondence: thomas-wassink@uiowa.edu
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reproduction in any medium, provided the or15q11-13 duplications [1] or 16p11.2 deletions [2]. Based
on heritability studies, while some phenotypic variability
may be due to environmental factors, a substantial portion
can be attributed to heritable ‘modifying’ factors that have
little effect on disease risk itself [3-5].
Identifying and studying modifying genes can be import-
ant clinically. In hypertension, for example, common vari-
ation in the renal NaCl-transporter SLC12A3 (NCCT)
gene, while only minimally associated with disease, is
strongly associated with biological traits related to blood
pressure [6] and is also the site of action for thiazidel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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neuropsychiatric disorders appear to be similar: genes of
neurotransmitter systems, while minimally associated with
the disorders, are more strongly associated with important
biological traits and are the sights of action of many psy-
chiatric medications [8].
We have previously investigated relationships between
genes of the serotonin system, including monoamine
oxidase A (MAOA), and the associated trait of brain
morphology in children with autism. Abnormalities of
the serotonin system have repeatedly been described in
children with autism, and MAOA is centrally involved
in synaptic processing of serotonin. While association
studies of MAOA variants in autism have produced
uneven results [9-11], the gene has been associated with
cognitive and emotional traits of relevance to the
disorder [12-15], and the MAOA protein is the primary
target for MAO inhibitors, an important class of psychi-
atric medication. We selected brain structure as an asso-
ciated trait because cortical enlargement is a replicable
phenotypic feature of autism thought to be intrinsically
related to the disease process [16]. We found that while
not associated with autism itself, a low activity allele of a
functional MAOA promoter polymorphism was associ-
ated with increased cerebral cortical gray and white mat-
ter volumes in children with autism but not in typically
developing children [9].
The generalizability of this result within autism spectrum
disorders (ASDs) is, however, unclear. Given that autism
comprises many different etiologies, we do not know
whether the association we observed would characterize all
cases or only certain etiologically distinct subgroups.
Single gene disorders that produce the autism pheno-
type, such as fragile X syndrome (FXS), can be useful
in elucidating the specificity of such effects. FXS is a
monogenic disorder with a characteristic behavioral
phenotype that often includes features of autism. Chil-
dren with FXS experience, for example, social anxiety
and avoidance, repetitive behaviors such as hand-flapping,
and impaired speech and communication [17,18]. Up to
one-third of children with FXS meet diagnostic criteria
for autism, and FXS is the most common known cause
of autism, accounting for 2% to 3% of cases. Children
with FXS also have characteristic patterns of brain
structure volumes that are similar in some respects but
that also differ from those seen in autism [18-21]. Thus
we tested whether an association between a genetic
variant and a biological measure that was identified in
idiopathic autism was also found in a single gene dis-
order commonly associated with autism. Results from
these analyses clarify the specificity of the original
MAOA finding and provide a model for investigating
interaction among specific genes on biological traits
of illness.Methods
Participant recruitment and clinical and behavioral
assessment
The study protocols were approved by the human sub-
jects committees at the Stanford University School of
Medicine and the University of North Carolina, Chapel
Hill (UNC). Consent was obtained from parents.
Children with autism were drawn from an ongoing
UNC longitudinal study of brain development in very
young children with autism [16]. These children were pri-
marily referred from nine specialty clinics for pervasive
developmental disorders in North Carolina (Treatment
and Education of Autistic and Related Communication
Handicapped Children (TEACCH) centers). Subjects
with autism were enrolled between 18 and 35 months
of age after receiving a clinical diagnosis of an autism
spectrum disorder. Medical records and developmental
history were reviewed. Subjects were excluded for hav-
ing evidence of a medical condition thought to be asso-
ciated with autism, including FXS, tuberous sclerosis,
gross central nervous system injury (for example, cerebral
palsy, significant perinatal or postnatal complications or
trauma, drug exposure), seizures, and significant motor or
sensory impairments.
Diagnosis was confirmed using the Autism Diagnostic
Interview-Revised (ADI-R) [22] and the Autism Diag-
nostic Observation Schedule-Generic (ADOS-G) [23].
Subjects were included if they met ADI-R algorithm cri-
teria for autism and obtained ADOS-G scores consistent
with autism. Diagnosis was reconfirmed at 4 years of
age. All of the cases met DSM-IV criteria for autistic dis-
order. Study approval was acquired from the University
of North Carolina institutional review board, and written
informed consent was obtained from parents or custo-
dial guardian for each subject. The total autism sample
comprises 51 children. DNA was available for 34 boys
from this sample, all of whom were Caucasian, with an
average age at the time of the scan of 2.71 ± 0.30 years.
Children with FXS were recruited using Stanford and
UNC registry databases, postings on the National Fragile
X Foundation Web site and in their quarterly newsletter,
and mailings to regional FXS organizations. Inclusion in
the FXS group required DNA testing that confirmed the
fragile X full mutation using the standard Southern blot
technique. Exclusion criteria included preterm birth
(<34 weeks gestation), low birth weight (<,2000 g), and
any serious medical or neurological condition affecting
growth and development (for example, seizure dis-
order, diabetes, or congenital heart disease). The total
FXS sample also now comprises 51 children who were
first imaged between the ages of 18 and 35 months.
DNA was available for 47 boys from this sample, all of
whom were Caucasian, with an average age at the time
of the scan of 2.90 ± 0.60 years. In addition, children
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and ADOS-G as described above; 17 FXS subjects met
diagnostic criteria for autism (FXS + ASD) while 30 did
not (FXS - ASD).
All children with FXS and/or autism were further
assessed with a battery of measures including the Mullen
Scales of Early Learning [24] , the Vineland Adaptive Be-
havior Scales [25], behavioral rating scales (for example,
Repetitive Behavior Scales), and a standardized neurode-
velopmental examination.
Lastly, we compared our results from the patient sam-
ples with those from a group of older typically develop-
ing children described in our previous report [9]. Briefly,
we acquired DNA from a sample of children who had
undergone an MRI scan at the University of Iowa Hos-
pital and Clinics as part of their involvement in another
study. Exclusion criteria for this group included presence
of braces, major medical, neurologic, or psychiatric ill-
ness, or history of learning disability (information ob-
tained from parents during screening process). Average
full scale IQ for this group was 112 (±18). Only geno-
types from boys in typically developing sample were ana-
lyzed, resulting in a cohort of 39 Caucasian boys with an
average age at the time of scan of 12.5 ± 2.21 years.
MRI acquisition
The FXS and autism participants underwent a multi-
modal magnetic resonance imaging (MRI) brain scan.
Participants were sedated during their MRI by a
pediatric anesthesiologist who administered and moni-
tored the sedation throughout the scan. MRI acquisition
was performed on General Electric 1.5-T Signa LX scan-
ners (GE Healthcare, Milwaukee, WI, USA) using stand-
ard transmit/receive 4-channel head coils. An identical
pulse sequence protocol was used at both the UNC and
Stanford sites that maximized contrast between gray
matter (GM), white matter (WM), and cerebrospinal
fluid (CSF) for the participants’ age range: (1) a coronal
T1 IR Prepared with T1 300 ms, TR 12 ms, TE 5 ms, 20°
flip angle, at 1.5 mm thickness with 1 NEX, 20 cm field
of view (FOV), and a 256 × 192 matrix; and (2) a coronal
PD/T2 2D dual FSE, TR 7200 ms, TE 17/75 ms, at
3.0 mm thickness with 1 NEX, 20 cm FOV, and a 256 ×
160 matrix. An MRI quality control phantom was
scanned after each subject at both sites to standardize
assessments over sites, individuals, and time. We also
performed extensive additional quality control proce-
dures and analyses to ensure comparability of scans
across the two sites, all of which are described in a pre-
vious publication [21].
The images for the typically developing adolescent
sample were obtained on a 1.5 Tesla GE Signa MR scan-
ner. Three different sequences were acquired for each
subject: T1, T2, and Proton Density. Processing of theimages after acquisition was done using a locally devel-
oped family of software programs called BRAINS (acro-
nym for Brain Research: Analysis of Images, Networks,
and Systems). Details of the image analysis are published
elsewhere [26-30]. Briefly, The T2 and proton density
images were aligned to the spatially normalized T1
image using an automated image coregistration pro-
gram. A Talairach-based atlas coordinate system was
overlaid onto each individual brain, aligning with ana-
tomical landmarks of that brain without normalization
to a standardized brain size [31]. These coordinates were
then used to generate automated measurements of
frontal, temporal, parietal, and occipital lobes, cerebellum,
and subcortical regions. This method permits morpho-
logical measurements to be made in non-normalized or
‘raw’ space.
Image processing
For all images, initial image processing to register and
align the T1 and PD/T2 scans into a standardized plane
was conducted with BRAINS2, which was developed at
the University of Iowa [27,30]. Images were processed
for tissue segmentation using an adaptation by our lab
of the Expectation Maximization Segmentation (EMS)
software originally developed at the Catholic University
of Leuven [32]. We also developed and used a probabil-
istic atlas for tissue segmentation of the 2-year-old brain.
The automated tissue segmentation protocol has been
previously described in detail [16] and was used to gen-
erate gray and white matter volumes for the frontal,
temporal, and combined parietal-occipital lobes, and for
the cerebellum.
Genotyping
For this study, we genotyped and analyzed the MAOA
promoter polymorphism. PCR amplification of the poly-
morphism was performed according to a previously de-
scribed protocol [33]. PCR products were electrophoresed
on 6% polyacrylamide gels that were stained with silver
and read by two independent raters with discrepancies re-
solved by regenotyping. The proper genotype grouping for
the MAOA promoter VNTR is based on functional ex-
pression data which shows that 3 and 5 repeat variants
have low enzymatic activity (MAOA-L) while 3.5 and 4 re-
peats show high activity (MAOA-H) [33]. As MAOA is an
X chromosome gene and only boys were analyzed, all ge-
notypes were hemizygous.
Statistical analysis
Analysis of covariance (ANCOVA) was performed in
SAS to test for relationships between genotypes and
brain structure volumes. Because some of the brain
structure volumes were not normally distributed, we
used non-parametric analogs of the ANCOVAs in which
Table 1 Ages and allele frequencies of study subjects
Idiopathic
autism
FXS - ASD FXS + ASD
MAOA allele High Low High Low High Low
n 21 13 20 10 10 7
Age, mean
± sd (years)
2.7 ± 0.4 2.8 ± 0.2 2.8 ± 0.7 2.9 ± 0.6 3.0 ± 0.6 3.0 ± 0.6
IQ 54 ± 7 52 ± 7 51 ± 4 50 ± 4 60 ± 12 54 ± 5
Adaptive
behavior
61 ± 6 58 ± 6 57 ± 6 57 ± 4 68 ± 12 60 ± 3
Estimate of IQ is from the Mullen Composite Standard Scale score.
Adaptive behavior estimate is from the Vineland Adaptive
Behavior Composite.
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values were analyzed instead of the raw values. The in-
dependent predictors were MAOA genotype, presence
or absence of FXS, and presence or absence of autism.
Structure volumes were the dependent measures and
covariates included age at the time of scan and the Vine-
land Adaptive Behavior composite score (which provided
more variance than the IQ measure derived from the
Mullen scale). We also tested all interaction terms,
which were kept in the model only if significant.
For those brain structure volumes that were signifi-
cantly influenced by MAOA genotype we calculated the
percent difference between the adjusted means for the
genotype groups. We also calculated eta2 (semi-partial
eta2 as implemented in SAS), an effect size statistic that
estimates the amount of variance in the dependents
measure accounted for by the independent measure after
removing effects of the covariates.
Determining appropriate significance thresholds for
the statistical tests is complex. We were following up
positive associations that were in a specific direction,
enabling the possibility of using one-tailed tests. In
addition, the regional brain structure volumes are highly
correlated (rather than independent), so that a strict
Bonferroni correction would be overly conservative. AsTable 2 Brain structure volumes by diagnosis and genotype
All subjects Autism on
High Low High
(n = 51) (n = 30) (n = 21)
Total brain volume 1261 ± 96 1330 ± 99 1271 ± 100 1
Frontal gray 246 ± 24 261 ± 18 251 ± 24
Frontal white 105 ± 11 114 ± 11 107 ± 11
Temporal gray 155 ± 13 165 ± 15 157 ± 13
Temporal white 43.4 ± 4.7 46.8 ± 5.5 41.5 ± 3.6
Parietal-occipital gray 252 ± 22 265 ± 20 253 ± 25
Parietal-occipital white 101 ± 10 108 ± 9.3 103 ± 10
Values are adjusted means ± standard deviations in cubic centimeters.a compromise, we have chosen to perform two-tailed
tests describing P values ≤0.05 as ‘nominally’ significant,
while presenting all test results and P values so that the
reader can decide.
Results
Table 1 shows the number of subjects, average ages, IQ
(Mullen), and adaptive functioning (Vineland) in each
genotype group. IQ and adaptive functioning were differ-
ent across diagnostic groups (Mullen: F = 7.89, P = 0.0008;
Vineland: F = 5.61, P = 0.006), with the FXS + ASD group
having higher scores than the other two groups. There
was no association, however, between genotype and age
(F = 0.02, P = 0.90), IQ (F = 0.96, P = 0.22), or adaptive
functioning (F = 3.37, P = 0.07).
Table 2 shows adjusted means of the cortical struc-
tures for the genotype groups within each diagnostic cat-
egory, and Table 3 shows the ANCOVA results. MAOA
genotype produced significant main effects on both gray
and white matter volumes across all the cortical lobes.
In all cases, the low activity allele was associated with
increased volumes, an effect that was most pronounced
in white matter (Figure 1). The FXS diagnostic grouping
produced nominally significant effects on frontal (F =
4.46, P = 0.04) and temporal GM volumes (F = 3.86, P =
0.05): individuals with FXS had smaller volumes of these
structures than individuals with idiopathic autism. There
were no significant effects of the autism diagnostic
grouping on cerebral cortical brain structure volumes.
There were no significant genotype-by-diagnosis interac-
tions because the effects were in the same direction
in the idiopathic autism, FXS - ASD, and FXS + ASD
groups and were of generally equal strength across the
groups. Subjects with low activity alleles had, on average,
3.5% to 6.7% greater volumes than subjects with high ac-
tivity alleles, and MAOA genotype accounted for ap-
proximately 10% to 15% of the variability in cortical lobe
gray and white matter volumes after removing effects of
the covariates.ly FXS - ASD FXS + ASD
Low High Low High Low
(n = 13) (n = 20) (n = 10) (n = 10) (n = 7)
334 ± 88 1246 ± 111 1338 ± 137 1254 ± 88 1315 ± 86
266 ± 16 238 ± 25 258 ± 23 243 ± 23 255 ± 16
116 ± 8.2 104 ± 15 113 ± 16 104 ± 11 110 ± 8.8
168 ± 16 151 ± 14 163 ± 17 153 ± 14 162 ± 12
45 ± 4.9 45.2 ± 5.5 47.9 ± 6.3 44.5 ± 4.9 50.9 ± 5.5
266 ± 15 249 ± 18 266 ± 32 251 ± 20 262 ± 16
109 ± 8 99 ± 8.9 108 ± 14 99 ± 9.5 106 ± 6.5
Table 3 Analysis of covariance results
MAOA genotype F tests
All patients Autism FXS
F P eta2 F P eta2 F P eta2
Total brain volume 8.51 0.005 0.10 3.66 0.07 – 4.24 0.05 0.09
Frontal gray 7.77 0.007 0.10 3.64 0.07 – 4.39 0.04 0.09
Frontal white 15.46 0.0002 0.16 10.58 0.003 0.25 5.71 0.02 0.09
Temporal gray 5.33 0.02 0.07 2.43 0.13 – 2.00 0.17 –
Temporal white 13.29 0.0005 0.14 13.84 0.0008 0.30 4.73 0.04 0.08
Parietal-occipital gray 6.72 0.01 0.09 2.71 0.11 – 2.92 0.10 –
Parietal-occipital white 9.89 0.003 0.12 4.61 0.04 0.12 5.00 0.03 0.11
Figure 1 MAOA promoter polymorphism alleles and brain structure volumes across diagnostic groups. The figure shows gray and white
matter volumes for three cerebral cortex lobes: frontal, temporal, and combined parietal and occipital. Individuals are separated according to
diagnostic group: IdASD = idiopathic autism spectrum disorder, FXS-ASD = fragile X syndrome without ASD, and FXS + ASD = fragile X syndrome
with ASD. Within diagnostic group, individuals are further stratified by genotype, with diamonds (◊) representing those with high activity and
crosses (+) those with low activity MAOA alleles. All values have been adjusted for the covariate of age. Red crosses show least squares means
(lsmeans) for each diagnosis-by-genotype group; the horizontal bar is the lsmean and the vertical is the standard error of the mean. For all three
diagnostic groups across all six brain regions, the low activity allele is associated with greater volumes than the high activity allele.
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dren had the high activity allele and 11 the low activity
allele. There were no significant differences in these chil-
dren for any brain structure volume based on MAOA
genotype (Figure 2).
Discussion
We have previously shown that a functional promoter
polymorphism of the MAOA gene is associated with
brain structure volumes in children with idiopathic aut-
ism [9]. Given the phenotypic overlap with autism, we
now tested for a similar association in children with the
fragile X syndrome (FXS). We found, as in idiopathic
autism, that the low-expressing allele was associated
with increased cerebral cortical gray and white matter
volumes in the FXS children, both those with and with-
out autism (Figure 1). These associations were not ob-
served in older typically developing children assessed in
our previous study (Figure 2). We thus demonstrate that
this modifying genetic effect on an endophenotypic trait
is found in two neurodevelopmental disorders, and we
demonstrate the utility of FXS and autism as a system
for testing relationships amongst specific genes within
the heterogeneity of ASDs.
The plausibility of the MAOA polymorphism pro-
ducing these brain effects is supported by multiple
lines of research. Serotonin influences numerous as-
pects of brain development, as well as ongoing synap-
tic activity throughout life [34,35]. Perturbations of
the serotonin system have been implicated in a varietyFigure 2 MAOA promoter polymorphism alleles and brain structure v
comparison with Figure 1, this figure shows gray and white matter volume
have been adjusted for age. In contrast to the children with autism and/or
different brain structure volumes in these children.of neuropsychiatric disorders, with particularly com-
pelling effects in autism [36-40]. MAOA is the primary
enzyme responsible for degrading synaptic monoamine
neurotransmitters, including serotonin, and levels of these
neurotransmitters in the brain vary in association with
levels of the MAOA protein [41-44].
Alterations in expression of MAOA are, in turn, associ-
ated with neuropsychiatric disorders. Two null mutations
cause severe phenotypes. Norrie’s disease is characterized
by mental retardation, autistic behavior, and motor
hyperactivity, and is caused by an X-chromosomal dele-
tion that includes MAOA [45,46], while Brunner’s
syndrome includes violent and criminal behavior in the
phenotype and is due to an MAOA stop mutation
[47,48]. The MAOA promoter polymorphism, by con-
trast, is associated with more moderate expression ef-
fects. The polymorphism is a 30 base pair VNTR that is
1.2 kb upstream of exon 1 [49]. When present as 3.5 or
4 copies, the repeat is associated with increased MAOA
expression, while 2, 3 or 5 copies are associated with
decreased expression [33,50]. The repeat has also been
associated with numerous less severe but more com-
mon neuropsychiatric phenotypes [51-54]. Of relevance
to autism, the low activity allele has been associated with
increased severity of a range of social and behavioral diffi-
culties, including sensory behaviors, arousal regulation,
aggression, social communication skills [54,55], a lower
IQ [54], and, through our previous work, cerebral cortical
enlargement [9]. This association with brain structure is
noteworthy because increased head circumference andolumes in typically developing control children. For purposes of
s for the three cortical lobes in typically developing children. Values
FXS, MAOA promoter polymorphism genotype is not associated with
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biological correlates of autism [16,56].
The current findings are consistent with a more gen-
eral relationship between serotonin and brain structure
suggested by our research. In addition to MAOA, we
have also tested a functional promoter polymorphism of
the serotonin transporter gene (SERT) [57]. Just as with
MAOA, we found that an allele associated with de-
creased expression of SERT is associated with increased
cerebral cortical gray and white matter volumes in idio-
pathic autism. For both genes, decreased expression is
associated with increased synaptic and central nervous
system (CNS) serotonin levels [41,42,58]. Thus a picture
begins to emerge of serotonin system genetic variation
influencing brain structure where increased serotonin
expression is associated with increased cerebral cortical
volumes in children with neurodevelopmental disorders,
particularly autism and FXS.
The findings also show how studying single gene dis-
orders can help to clarify the specificity of genetic effects
found in more complex, heterogeneous disorders. Aut-
ism has a highly variable phenotype, suggesting an array
of interacting genetic factors that influence the expres-
sion of disease. FXS is a monogenic disorder in which
some children have phenotypic features of autism while
others do not. Through our examination, we find that
the MAOA polymorphism produces the same effects
on brain structure in three groups of affected children:
those with idiopathic autism, those with FXS and aut-
ism, and those with FXS but no autism. We do not find
any effect of the polymorphism on brain structure in
typically developing children, though we do note that
this is not an ideal comparison group because they are
older than the patients and their images were acquired
through a different scan protocol.
Furthermore, though an understanding of why the
MAOA polymorphism would produce brain effects in
some children but not others is not known, studies of
mice support this type of interaction. Mice of different
genetic backgrounds display markedly different patterns of
social behavior, with some strains exhibiting social defi-
cits resembling those seen in autism [59,60]. The same
genetic defect placed on these different backgrounds
can produce strikingly different phenotypes. Moy et al.,
for example, reported that targeted disruption of Fmr1
produced sociability deficits in FVB/129 mice but not
in C57BL/6 J mice [61]. More closely related to our
study, Page et al. used mice to examine interactive ef-
fects of two autism-related genes on brain structure
[62]. Mice haploinsufficient for either the SERT or
PTEN gene had enlarged brains as well as deficits in so-
cial interaction. After crossing, mice haploinsufficient
for both genes had more substantial brain enlargement
and more severe sociability deficits.Conclusion
In our study examining two gene variants (the MAOA
polymorphism and the FXS anomaly) and brain volume
in humans, we do not find evidence of a combinatorial
effect, additive or otherwise. Rather, we find that the as-
sociation of MAOA with brain structure in similar in
children with either FXS or autism or both. The rela-
tionship does not generalize to older typically developing
children; testing in additional disorders will further clar-
ify the boundaries of the association.
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